Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Monitoring disease progression and therapeutic response in a disseminated tumor model for non-hodgkin lymphoma by bioluminescence imaging

 
: Köberle, Margarethe; Müller, Kristin; Kamprad, Manja; Horn, Friedemann; Scholz, Markus R.

:
Volltext (PDF; )

Molecular imaging 14 (2015), Nr.6, S.400-411
ISSN: 1535-3508
ISSN: 1536-0121
Englisch
Zeitschriftenaufsatz, Elektronische Publikation
Fraunhofer IZI ()

Abstract
Xenograft tumor models are widely studied in cancer research. Our aim was to establish and apply a model for aggressive CD20- positive B-cell non-Hodgkin lymphomas, enabling us to monitor tumor growth and shrinkage in a noninvasive manner. By stably transfecting a luciferase expression vector, we created two bioluminescent human non-Hodgkin lymphoma cell lines, Jeko1(luci) and OCI-Ly3(luci), that are CD20 positive, a prerequisite to studying rituximab, a chimeric anti-CD20 antibody. To investigate the therapy response in vivo, we established a disseminated xenograft tumor model injecting these cell lines in NOD/SCID mice. We observed a close correlation of bioluminescence intensity and tumor burden, allowing us to monitor therapy response in the living animal. Cyclophosphamide reduced tumor burden in mice injected with either cell line in a dose-dependent manner. Rituximab alone was effective in OCI-Ly3(luci)-injected mice and acted additively in combination with cyclophosphamide. In contrast, it improved the therapeutic outcome of Jeko1(luci)-injected mice only in combination with cyclophosphamide. We conclude that well-established bioluminescence imaging is a valuable tool in disseminated xenograft tumor models. Our model can be translated to other cell lines and used to examine new therapeutic agents and schedules.

: http://publica.fraunhofer.de/dokumente/N-367154.html